Nanoparticles-mediated drug delivery approaches for cancer targeting: a review

被引:113
作者
Sultana, Shaheen [1 ]
Khan, Mohd Rashid [1 ]
Kumar, Mukesh [1 ]
Kumar, Sokindra [1 ]
Ali, Mohammed [2 ]
机构
[1] RV Northland Inst, Greater Noida 203207, UP, India
[2] Jamia Hamdard, New Delhi, India
关键词
Nanoparticles; nanoprecipitation; active targeting; passive targeting; ligands; SOLID LIPID NANOPARTICLES; GLYCOL)-MODIFIED GELATIN NANOPARTICLES; DOXORUBICIN-LOADED NANOPARTICLES; GOLD NANOPARTICLES; MONOCLONAL-ANTIBODY; IN-VITRO; GENE DELIVERY; P-GLYCOPROTEIN; POLY(EPSILON-CAPROLACTONE) NANOPARTICLES; PEGYLATED NANOPARTICLES;
D O I
10.3109/1061186X.2012.712130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cancer has become the leading cause of death among different populations of the world. The treatment is limited to chemotherapy, radiation, and surgery. Selective targeting to the tumor cells is possible by nanoparticles-based drug delivery system. It maximizes the drug concentration at the desired target and protects the surrounding healthy tissues at the same time. To improve the targeting potential of the anticancer drugs, nanoparticles were optimized for the size and surface characteristics to enhance their circulation time and targeting efficiency. Passive targeting involves surface modification with polyethylene glycol to avoid its elimination by natural body defense mechanism. Active targeting involves chemical interaction with certain antigen, receptors, and genes which are over expressed during progression of disease. In addition, the article highlights recent developments in "smart"-stimulus-responsive-drug carriers designed to enhance the localization and efficacy of therapeutic payloads as compared with free drug. Enhanced targeting potential, imaging, and controlled release of drugs or therapeutic molecules could be possible through multi-functional nanocarrier. Such multi-faceted, versatile nanocarriers and drug delivery systems promise a substantial increase in the efficacy of diagnostic and therapeutic applications in pharmaceutical sciences.
引用
收藏
页码:107 / 125
页数:19
相关论文
共 212 条
[1]   Edrecolomab (monoclonal antibody 17-1A) [J].
Adkins, JC ;
Spencer, CM .
DRUGS, 1998, 56 (04) :619-626
[2]   Ligand based dendritic systems for tumor targeting [J].
Agarwal, Abhinav ;
Saraf, Surbhi ;
Asthana, Abhay ;
Gupta, Umesh ;
Gajbhiye, Virendra ;
Jain, Narendra K. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 350 (1-2) :3-13
[3]   Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers) [J].
Ahmadvand, Davoud ;
Rahbarizadeh, Fatemeh ;
Moghimi, Seyed Moein .
CURRENT OPINION IN BIOTECHNOLOGY, 2011, 22 (06) :832-838
[4]  
Ailar N, 2010, J BIOMEDICAL NANOTEC, V6, P360
[5]   Magnetic drug targeting - Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment [J].
Alexiou, C ;
Jurgons, R ;
Schmid, RJ ;
Bergemann, C ;
Henke, J ;
Erhardt, W ;
Huenges, E ;
Parak, F .
JOURNAL OF DRUG TARGETING, 2003, 11 (03) :139-149
[6]   Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles [J].
Anhorn, Marion G. ;
Wagner, Sylvia ;
Kreuter, Joerg ;
Langer, Klaus ;
von Briesen, Hagen .
BIOCONJUGATE CHEMISTRY, 2008, 19 (12) :2321-2331
[7]  
[Anonymous], J BIOMATER SCI POLYM
[8]  
Baker James R Jr, 2009, Hematology Am Soc Hematol Educ Program, P708, DOI 10.1182/asheducation-2009.1.708
[9]   Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA [J].
Beloor, Jagadish ;
Choi, Chang Seon ;
Nam, Hye Yeong ;
Park, Minsun ;
Kim, Sung Hwa ;
Jackson, Andrew ;
Lee, Kuen Yong ;
Kim, Sung Wan ;
Kumar, Priti ;
Lee, Sang-Kyung .
BIOMATERIALS, 2012, 33 (05) :1640-1650
[10]   Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice [J].
Bibby, DC ;
Talmadge, JE ;
Dalal, MK ;
Kurz, SG ;
Chytil, KM ;
Barry, SE ;
Shand, DG ;
Steiert, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 293 (1-2) :281-290